José Trevejo

Biography

José Trevejo is a physician-scientist with more than 20 years of experience in infectious disease research and development and clinical practice. Prior to joining Visterra, Dr. Trevejo served as Medical Director at Genentech, Inc., where he led the clinical and biomarker strategy for development of an influenza biological therapy that rapidly progressed from preclinical to phase 2 clinical trials. Previously, he was the Medical Director and Clinical Disease Area Lead for Infectious Diseases at Vertex Pharmaceuticals, where he led the clinical development of an influenza small molecule therapy and participated in the filing of telaprevir, one of the first approved direct acting antivirals for hepatitis C. Dr. Trevejo started his career as a principal investigator and scientist at the Draper Laboratory, where he conducted diagnostics research and development, and managed Department of Defense-supported programs relating to emerging influenza countermeasures. Dr. Trevejo received his BS in Applied Mathematics from UCLA and his MD and PhD from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Memorial Sloan Kettering. He completed his clinical training at Harvard Medical School, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center and is a licensed physician with board certification in infectious disease.

Research Interest

infectious disease research and development and clinical practice